A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

Inclusion Criteria

• •Sign a written Informed Consent Form, which must meet the following requirements
• •* Be willing to participate in the study and able to sign the informed consent form;
• •* Be willing and able to complete all study-specific procedures and visits;
• •PsA trial participant disease characteristics
• •* Aged 18 to 70 years（inclusive）;
• •* BMI ≥ 18 kg/m² at screening; diagnosed with PsA for at least 3 months prior to screening, and meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening;
• •* Active arthritis at screening and at baseline (Day 1);
• •* Has failed or was intolerant to at least one prior therapy;
• •* If receiving a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD), trial participants must be on only one DMARD, which must have been administered for at least 3 months prior to screening, with a stable dose for at least 28 days prior to the first dose;
• •* If using NSAIDs, the dose must have been stable for at least 14 days before the first dose;
• •* If using oral corticosteroids, the dose must have been stable for at least 14 days before the first dose;
• •* Topical treatments for plaque psoriasis must have remained stable for at least 14 days before the first dose;
• •Women of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of the study; men must agree to use effective contraception during the study and for 6 months after the end of the study
• •* Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection; or syphilis infection requiring treatment;
• •Abnormal physical examination or laboratory findings;
• •Other:
• •* History of any major drug allergy; known allergy to any excipient of the investigational product;
• •* Inability to comply with the trial protocol;
• •* History of substance abuse with inability to abstain or presence of a psychiatric disorder;
• •* Participation in another clinical trial and use of another investigational drug (other than for psoriatic arthritis) within 4 weeks prior to the first dose, based on the date of discontinuation from the previous trial;
• •* Planned or previous allogeneic bone marrow transplantation or solid organ transplantation;
• •* Any condition that, in the investigator's judgment, poses a serious risk to the safety of the trial participant or affects the participant's ability to complete the study.